Recombinant Cell Assay for Botulinum Neurotoxin Serotype Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to assess Botulinum Neurotoxin (BoNT) activity and distinguish between different BoNT serotypes, and to identify BoNT inhibitors and proteases in environmental samples, particularly in measuring the degradation of C-terminal markers subject to N-end rule degradation.
Innovation Solution
A cell-based assay using recombinant cells that express BoNT substrates with labels at their C-terminus, which are cleaved by BoNT, generating fragments subject to ubiquitin proteasome degradation, allowing for measurement of label expression and differentiation between proteases based on degradation patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to assess BoNT activity, then the assessment can be performed, but the methods lack the ability to distinguish between different BoNT serotypes and identify inhibitors
Solution Approach 1:
The assay segments the BoNT detection process into distinct functional components: a BoNT substrate that is cleaved by the toxin, generating a C-terminal fragment that serves as a specific marker for each serotype. This segmentation allows simultaneous detection of BoNT activity and serotype identification through the specific degradation patterns of the substrate fragments.
Solution Approach 2:
The patent introduces a recombinant cell as an intermediary system that expresses the BoNT substrate and processes the cleaved fragments through the ubiquitin-proteasome pathway. This intermediary enables the conversion of BoNT proteolytic activity into measurable signals (label expression changes) while providing the cellular machinery necessary for fragment degradation and signal amplification.
2Measurement precision
If a cell-based assay with recombinant cells is used, then accurate assessment of BoNT activity and serotype differentiation is achieved, but the device complexity increases
Solution Approach 1:
The recombinant cell serves multiple functions simultaneously: it expresses the BoNT substrate, provides the ubiquitin-proteasome degradation pathway, and generates the measurable signal through label expression changes. This multi-functionality reduces the need for separate assay components and simplifies the overall system despite the cellular complexity.
Solution Approach 2:
The recombinant cell autonomously performs substrate expression, proteolytic cleavage processing, fragment degradation through the proteasome pathway, and signal generation. The cell's endogenous machinery handles multiple steps of the assay, reducing the need for external reagents and manual intervention.
3Adaptability or versatility
If C-terminal labeled substrates are used that are degraded by the ubiquitin proteasome pathway, then the ability to distinguish proteases based on degradation patterns is improved, but the difficulty of detecting and measuring increases
Solution Approach 1:
The assay utilizes label expression changes (analogous to color changes in optical assays) as a readable signal. The C-terminal label's expression level changes in response to substrate cleavage and fragment degradation, providing a quantitative measure of protease activity and fragment stability that can be detected through standard molecular biology techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate assessment of BoNT activity, differentiation between BoNT serotypes, and identification of inhibitors by measuring label expression and degradation, providing a reliable method for detecting protease activity and inhibitors in environmental samples.
Implementation Method 1
The BoNT substrate generates a N-terminus fragment and a C-terminus fragment upon cleavage by the BoNT
Implementation Method 2
The C-terminus fragment is degraded by the recombinant cell's ubiquitin proteasome pathway
Data Source
AI summary
A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease.